1. An Overview of Aspergillosis in Contemporary Medicine {#sec1-jof-03-00005}
========================================================

Members of the *Aspergillus* genus are ubiquitous saprobe fungi that can be found worldwide, occurring mainly in air, soil, water, plants, food, and inanimate surfaces \[[@B1-jof-03-00005]\]. *Aspergillus* is the most important pathogenic filamentous fungus in humans, causing a wide spectrum of clinical syndromes, highlighting invasive aspergillosis (IA), chronic pulmonary aspergillosis (CPA), and allergic bronchopulmonary aspergillosis (ABPA) \[[@B2-jof-03-00005],[@B3-jof-03-00005],[@B4-jof-03-00005]\].

In the invasive forms, the inhalation of *Aspergillus* conidia is the primary acquisition route, due to the high incidence of small airborne conidia. Therefore, the conidia can be inhaled and colonize the sinuses, afterwards evolving into the lower respiratory tract by specific circumstances \[[@B1-jof-03-00005],[@B5-jof-03-00005]\]. Direct contact transmission has been associated with the contamination of biological prostheses and catheters. Moreover, the propagules can also be inoculated in the human host by trauma, causing cutaneous infections and fungal keratitis \[[@B1-jof-03-00005],[@B6-jof-03-00005],[@B7-jof-03-00005],[@B8-jof-03-00005]\].

The substantial increase in the occurrence of IA is mainly due to a larger number of patients exposed to risk conditions, including primary immunodeficiency diseases, hematological malignancies, prolonged neutropenia or neutrophil disorders, corticosteroids (dose and duration), stem cell and solid organ transplantation, and a genetic disease called chronic granulomatous disease \[[@B9-jof-03-00005],[@B10-jof-03-00005],[@B11-jof-03-00005],[@B12-jof-03-00005],[@B13-jof-03-00005]\]. The mortality rates of IA are high and vary according to patient population, ranging from 38% in individuals with acute myeloid leukemia (AML), 50%--60% in solid organ transplant, and 70%--85% in other immunocompromised patients \[[@B11-jof-03-00005],[@B14-jof-03-00005]\].

Unlike invasive aspergillosis, CPA occurs mostly in immunocompetent patients; it has been regarded as a major global health problem and is estimated to have a prevalence of 3 million cases \[[@B15-jof-03-00005],[@B16-jof-03-00005]\]. This number is even higher when the issue is ABPA---it is estimated that this disease affects approximately 4 million adults \[[@B15-jof-03-00005]\]. It is worth mentioning that tuberculosis (particularly in developing countries), as well as the high occurrence of chronic obstructive pulmonary disease (COPD), contributes to the high rate of CPA, while the huge worldwide burden of asthma contributes to the incidence rate of ABPA \[[@B16-jof-03-00005],[@B17-jof-03-00005],[@B18-jof-03-00005]\].

In recent years, a large number of antifungal agents have become available for use in aspergillosis, such as echinocandins and new triazoles. On the other hand, different medical centers worldwide reported a large number of IA cases, with a treatment failure rate exceeding 50% of the cases evaluated \[[@B19-jof-03-00005],[@B20-jof-03-00005]\]. Furthermore, individuals with CPA and ABPA represent the main patients with therapeutic failures due to triazole resistance, once they require long-term azole therapy \[[@B15-jof-03-00005],[@B17-jof-03-00005]\].

There is a great interest in the detection of triazole-resistant strains in order to discriminate whether the determinants of treatment failure are related to the limitations of clinical and immunological conditions of the host, or to decreased antifungal activity associated with the drug used in the treatment \[[@B19-jof-03-00005],[@B20-jof-03-00005]\]. In this context, this review summarizes the epidemiology, management, and extension of azole resistance in *A. fumigatus* worldwide and its potential impact in Latin American countries, emphasizing its relevance to clinical practice.

2. Methods {#sec2-jof-03-00005}
==========

Articles regarding triazole resistance in *A. fumigatus* were identified and reviewed using the Scientific Electronic Library Online and Medline databases through January 2017. Articles were reviewed regardless of the language or the date of publication, and were retrieved using the following keywords: *Aspergillus fumigatus*, aspergillosis, antifungal susceptibility, azole resistance, *CYP51A*. Each term was combined with the following keywords: Latin America, South America, developing world, Central America, Colombia, and Brazil. During the analysis, an exhaustive effort was made to collect all available information on epidemiology, clinical implications, and management of triazole resistance worldwide and in Latin America.

3. Global Scenario of Resistance to Azoles {#sec3-jof-03-00005}
==========================================

In antifungal resistance involving *Aspergillus*, two events have been observed: (i) primary or intrinsic resistance to azole and other antifungal agents; and (ii) secondary or acquired azole resistance in *A. fumigatus* isolates \[[@B21-jof-03-00005]\].

Primary resistance to amphotericin B is well recognized in *A. terreus*, and in some *A. flavus* and *A. ustus* isolates \[[@B21-jof-03-00005],[@B22-jof-03-00005],[@B23-jof-03-00005],[@B24-jof-03-00005]\]. Different species of *Aspergillus* genus belonging to the same section may present distinct antifungal susceptibility profiles. Recently, it has also been demonstrated in several species in the section *Fumigati*. It is known, for example, that *A. lentulus*, *A. udagawae*, *A. pseudofisheri*, *A. fumigatiffinis*, *A. thermomutatus*, and *A. viridinutans (Aspergillus* section *Fumigati*) have shown decreased susceptibility to several antifungal agents, including amphotericin B, azoles, and echinocandins \[[@B19-jof-03-00005],[@B25-jof-03-00005],[@B26-jof-03-00005],[@B27-jof-03-00005]\].

More recently, a multicenter international surveillance network reported a rate of triazole resistance of 3.2% amidst section *Fumigati* strains. Among all resistant isolates, 78% were *A. fumigatus sensu stricto*, and 22% were sibling species (*A. udagawae*, *A. thermomutatus*, and *A. lentulus*) \[[@B2-jof-03-00005],[@B28-jof-03-00005]\]. In 2015, Bastos et al. \[[@B29-jof-03-00005]\] described the first Brazilian case of pulmonary invasive aspergillosis caused by *A. lentulus*, reporting a strain resistant to amphotericin B and azoles (itraconazole and voriconazole). In another Brazilian study, high minimum inhibitory concentration (MIC) values against itraconazole and voriconazole (2 and 16 µg/mL, respectively) were observed for one isolate of *A. thermomutatus* \[[@B30-jof-03-00005]\]. Considering that different species may present distinct susceptibility profiles, species identification has become an important predictor of the clinical outcome \[[@B31-jof-03-00005]\].

Although *A. fumigatus* is generally susceptible to these azole antifungals, acquired resistance is increasingly being reported over the last few years \[[@B32-jof-03-00005],[@B33-jof-03-00005],[@B34-jof-03-00005]\]. These antifungal agents have affinity for heme prosthetic group, found in several enzymes participating in ergosterol biosynthesis---an essential component of the fungal cell membrane \[[@B35-jof-03-00005]\]. The specific target of azoles is the cytochrome P450-dependent enzyme lanosterol 14*α*-demethylase (Cyp51A). The main resistance mechanism appears to be mutations in genes (*CYP51A* and *CYP51B*) encoding the azole target enzyme, which accounts for over 90% of resistance cases \[[@B36-jof-03-00005],[@B37-jof-03-00005]\].

Some mutations are responsible for multi-azole resistance, and such resistance has a great impact on the outcome of patients with both invasive aspergillosis and chronic disease \[[@B38-jof-03-00005],[@B39-jof-03-00005]\]. Most of the azole resistant strains harbor the TR~34~/L98H mutation in the *CYP51A* gene, which consists of substitutions of leucine 98 for histidine (L98H) in addition to the presence of two copies of a 34-bp sequence tandem in the promoter of the *CYP51A* gene, resulting in an overexpression of the *CYP51A* \[[@B34-jof-03-00005],[@B35-jof-03-00005],[@B40-jof-03-00005],[@B41-jof-03-00005],[@B42-jof-03-00005],[@B43-jof-03-00005]\]. These mutations have been described as occurring in environmental and clinical isolates of *A. fumigatus* found in numerous countries in the Europe, China, the Middle East, India, Africa, Australia, Turkey, and most recently in Colombia \[[@B17-jof-03-00005],[@B44-jof-03-00005]\].

Recently, a novel *CYP51A*-mediated resistance mutation that leads to high-level voriconazole resistance---TR~46~/Y121F/T289A---has been also described as occurring in environmental and clinical isolates of *A. fumigatus* found in Europe, India, Africa, and Latin America \[[@B17-jof-03-00005],[@B35-jof-03-00005],[@B44-jof-03-00005],[@B45-jof-03-00005],[@B46-jof-03-00005],[@B47-jof-03-00005],[@B48-jof-03-00005],[@B49-jof-03-00005],[@B50-jof-03-00005],[@B51-jof-03-00005],[@B52-jof-03-00005],[@B53-jof-03-00005],[@B54-jof-03-00005]\].

Specific mutations in *CYP51A* may confer resistance to one, two, or all triazoles. In fact, these mutations have not only been associated with resistance to itraconazole, posaconazole, and voriconazole, but also with other azoles. Isavuconazole---a triazole which has only recently been licensed for use in humans---showed decreased in vitro activity and reduced in vivo efficacy against *A. fumigatus* strains harboring the resistance mechanisms described above \[[@B17-jof-03-00005],[@B55-jof-03-00005],[@B56-jof-03-00005],[@B57-jof-03-00005],[@B58-jof-03-00005]\].

It is interesting to comment that there has been a predominance of TR~34~/L98H and TR~46~/Y121F/T289A resistance mechanisms in clinical isolates from patients exposed, or not, to these drugs, as well as in environmental isolates. Between 64% and 71% of multi-azole resistance in *A. fumigatus* strains has been reported in patients with IA who were not previously exposed to azole treatments and who could be considered azole-naive \[[@B4-jof-03-00005],[@B41-jof-03-00005],[@B59-jof-03-00005],[@B60-jof-03-00005]\].

Concurrent genetic studies of worldwide *A. fumigatus* isolates harboring the TR~34~/L98H resistance mechanism suggested clonal expansion of a common resistant ancestor \[[@B35-jof-03-00005],[@B61-jof-03-00005]\]. This could easily occur, given that environmental dissemination of conidia can be facilitated due to their tiny size and their ability to cover thousands of miles in the air \[[@B1-jof-03-00005],[@B6-jof-03-00005],[@B17-jof-03-00005],[@B62-jof-03-00005],[@B63-jof-03-00005]\]. In addition, *Aspergillus* spores are released from different reservoirs, and often remain in the air for prolonged periods \[[@B1-jof-03-00005],[@B6-jof-03-00005]\].

Another route of azole resistance selection is through long-term azole exposure, particularly common in individuals with chronic forms of aspergillosis (aspergillomas: high fungal burden and chronic cavitary pulmonary) \[[@B17-jof-03-00005],[@B19-jof-03-00005],[@B64-jof-03-00005]\]. In this case, some researchers suggest that there is evidence of fungal evolution within the lung, since strains of identical genotype with distinct susceptibility profiles have been detected \[[@B65-jof-03-00005]\]. Azole resistance has been common in this population of patients, and the resistance mechanisms are quite varied and---at first---caused by non-environmental mutations \[[@B17-jof-03-00005],[@B64-jof-03-00005]\]. Moreover, multiple resistance mechanisms can be found in different colonies from a single specimen \[[@B17-jof-03-00005]\].

Currently, azole resistance has been much debated, given that it is an aggravating threat to human health, since the management of patients with resistant isolates and its detection is extremely complex, and there are not established guidelines. Furthermore, is important to highlight that these mutations have been found worldwide, signaling a possible extension of the problem \[[@B4-jof-03-00005]\].

4. Epidemiology of Triazole Resistance in *A. fumigatus* in Latin American Countries {#sec4-jof-03-00005}
====================================================================================

Although the triazole resistance in *A. fumigatus* has been an extensively debated topic, little is known about this problem in Latin America. Until now, only three studies evaluated strains recovered from these regions, as illustrated in [Figure 1](#jof-03-00005-f001){ref-type="fig"}.

Le Pape et al. \[[@B44-jof-03-00005]\] evaluated 60 soil samples from flower fields and greenhouses in the outskirts of Bogotá, Colombia. The isolates were recovered from a region with a high usage of tebuconazole and difeconazole. From these samples, 20 *A. fumigatus* strains were evaluated for *CYP51A* gene alterations. Among the strains studied, 19 showed changes in *CYP51A* gene, with 17 isolates presenting TR~46~/Y121F/T289A, 1 with TR~34~/L98H and 1 with TR~53~. In this study, no clinical isolates were investigated.

Van der Linden et al. \[[@B28-jof-03-00005]\] performed a multicenter international surveillance network in order to determine the prevalence of azole resistance in clinical *Aspergillus* isolates in several countries worldwide. A total of 3788 *Aspergillus* isolates were screened in 22 medical centers from 19 countries. Among these isolates, 64 strains were recovered from 57 Brazilian patients. Triazole-resistant phenotypes were not detected in Brazilian isolates by phenotypic screening-method using a four-well plate format with agar supplemented with itraconazole. Unlike the Colombian study, only clinical isolates were evaluated. In addition, the amount of strains investigated was not representative of the whole country, given that the strains were collected in two out of 26 federated states. On the other hand, it is worth noting that the presence of gene changes does not necessarily indicate in vitro resistance.

More recently, Leonardelli et al. \[[@B8-jof-03-00005]\] described the first report in South America of a clinical *A. fumigatus* strain carrying the substitution G54E at *CYP51A* associated with itraconazole resistance from an Argentine patient with fungal keratitis. Considering that the patient had never received any treatment with azole before, the authors suggested that the patient may have acquired this resistant isolate from the environment.

On the basis of these studies, azole resistance in Latin America is an issue that needs to be extensively explored, because it displays the two relevant scenarios for the development of triazole resistance in *A. fumigatus*: (i) environmental route due to increased usage of pesticides in agriculture; and (ii) prolonged azole exposure in CPA patients, although this disease is neglected in Latin America, particularly in geographic areas where tuberculosis is endemic. In the latter case, it is worth mentioning that there is a large contingent of patients with tuberculosis that evolves with residual cavities at the end of treatment of mycobacteriosis, becoming patients at risk for the development of CPA throughout life.

Therefore, there is a need to conduct antifungal resistance surveillance studies using clinical and environmental isolates from different geographic regions in patients exposed, or not, to these drugs, in order to establish the adequate management of patient and infection control.

5. Clinical Implications and the Management of Azole-Resistant Aspergillosis {#sec5-jof-03-00005}
============================================================================

Currently, various antifungal drugs for systemic use are commercially available for the treatment of invasive fungal infections, including different amphotericin B formulations, 5-fluorocytosine, triazoles (itraconazole, voriconazole, posaconazole, and isavuconazole), and echinocandin \[[@B19-jof-03-00005],[@B20-jof-03-00005]\]. According to the latest guidelines elaborated by Walsh et al. \[[@B66-jof-03-00005]\], voriconazole is the first drug of choice for the treatment of IA, and lipid formulations of amphotericin B ([L]{.smallcaps}-AmB) are an effective alternative. Moreover, posaconazole and caspofungin are recommended in the treatment of refractory IA or in patients intolerant to other therapies. Azole antifungals are still recommended for aspergillosis prophylaxis in hematopoietic stem cell transplantation (HSCT) recipients with graft-versus-host disease (GVHD) and in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome \[[@B66-jof-03-00005]\]. However, as discussed earlier, the use of triazoles has been compromised by the emergence of azole resistance in *A. fumigatus* \[[@B17-jof-03-00005]\].

Various reports indicated a high mortality rate in patients with documented azole-resistant IA \[[@B41-jof-03-00005],[@B67-jof-03-00005]\]. Given the high and rising triazole resistance rates and the absence of management guidelines for patients with aspergillosis, a group that comprised 21 experts (representatives of medical, microbiological and pharmacological areas) from 11 countries proposed some changes in the treatment of patients with azole-resistant *A. fumigatus* \[[@B17-jof-03-00005]\]. Briefly, some recommendations are described below.

For patients with IA in regions with epidemiological evidence of azole resistance in environmental isolates, new therapeutic strategies were suggested. Recommendations were elaborated based two parameters: (i) levels of environmental azole resistance of 5% to 10%; and (ii) azole resistance rate \>10%.

In the first case (resistance rate due to environmental mechanism of 5% to 10%), approximately half the panel advocated for voriconazole as the first-line therapy, while the other half backed the usage of [l]{.smallcaps}-AmB or a combination of voriconazole and an echinocandin. On the other hand, in regions with an environmental azole resistance rate \>10%, the panel advocated either for a combination of voriconazole plus an echinocandin or [l]{.smallcaps}-AmB monotherapy as initial empiric therapy. In fact, these parameters were recommended in IA with these levels of resistance, pending susceptibility data.

In cases of CPA, the management of patients is even more complicated, assuming that these individuals require long-term oral treatment, and azoles are the only oral agent available. Therefore, the panel suggested that these drugs should remain as the first line therapy regardless of environmental resistance rates. During the course of the disease, if a patient develops resistance to one or two azoles, it was agreed that therapy should be replaced by an alternative azole to which the fungus is susceptible. Intravenous therapy with a non-azole agent was highly advised in the case of pan-azole resistance. It is important to mention the same management principles were also considered for patients with ABPA, *Aspergillus* bronchitis, and severe asthma with fungal sensitization.

Early diagnosis of resistance---mainly in regions with high azole resistance rates---is another factor that may contribute to the adequate management of patients. The same expert group mentioned above agreed that clinical samples should be recovered prior to therapy, and tested using culture-based methods for patients with IA. In this case, all *Aspergillus* isolates obtained should be identified to species section level and have their susceptibility profile established by reference laboratories or the local clinical laboratory \[[@B68-jof-03-00005]\]. If an azole-resistant *A. fumigatus* is identified, molecular resistance mechanisms should be detected for epidemiological purposes \[[@B67-jof-03-00005]\].

Accordingly, in order to improve the diagnosis in patients with CPA, some recommendations were proposed by a panel of experts, highlighting: (i) regular culture and susceptibility testing of all isolates from patients on long-term azole therapy; and (ii) testing of multiples colonies from sputum cultures and using primary plates to detect resistance \[[@B69-jof-03-00005]\].

Unluckily, microbiological diagnosis of aspergillosis and triazole resistance is limited by poor culture yield \[[@B3-jof-03-00005],[@B70-jof-03-00005]\]. Considering the low efficiency of culture, commercial methods that allow fast and accurate detection of azole resistance need to be validated from primary samples \[[@B3-jof-03-00005],[@B67-jof-03-00005],[@B70-jof-03-00005]\]. When this is not possible, susceptibility testing of *A. fumigatus* isolates prior to and during antifungal treatment can be a useful tool instead.

In resource-scarce countries (as is the case of most Latin American countries), clinical implications regarding early diagnosis and effective treatment of azole-resistant aspergillosis are limiting factors in patient management, representing a huge challenge. Additionally, alternative therapeutic options such as [l]{.smallcaps}-AmB have the highest cost and require adequate medical infrastructures to allow intravenous administration \[[@B4-jof-03-00005]\].

6. Final Considerations {#sec6-jof-03-00005}
=======================

Although azole resistance has been reported in six continents, little is known about the actual frequency of azole resistance in *Aspergillus* isolates globally, mainly because most medical centers do not perform routine susceptibility testing. Moreover, azole resistance may be underestimated by culture-based diagnosis \[[@B3-jof-03-00005],[@B67-jof-03-00005],[@B70-jof-03-00005]\]. Diagnosis of azole resistance in negative cultures is a substantial challenge, since the current biomarkers---such as galactomannan and 1.3 β, [d]{.smallcaps}-glucan---are not permissible for identification of species and still less for performing in vitro susceptibility testing.

Information about azole resistance is still very limited in Latin American countries. Although only two studies detected azole resistance in environmental and clinical isolates, this does not mean that they are exempt from this problem---it means that they are unaware of it. However, it is essential to join efforts to promote monitoring of clinical and environmental isolates as a key to a better understanding of the magnitude of the problem.
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